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O
ver the past several years, there 
has been growing concern 
about selective publication of 
clinical trial results [1,2]. The debate 
has intensiﬁ  ed since New York State 
Attorney General Elliot Spitzer ﬁ  led 
suit against GlaxoSmithKline on June 
2, 2004, alleging that the company was 
hiding data regarding the efﬁ  cacy and 
safety of selective serotonin reuptake 
inhibitors in pediatric patients with 
depression [3]. 
The two most frequently suggested 
remedies for the selective reporting 
of clinical trials results have been 
to register all clinical trials and to 
make their results publicly available. 
Registries have been called for at least 
as far back as 1974; hundreds have 
in fact already been established [4]. 
Shortcomings of registries include the 
fact that they are often not coordinated 
and that participation is often voluntary 
and—in cases where they are mandated 
by legislation—difﬁ  cult to enforce. For 
example, ClinicalTrials.gov, a registry 
authorized by the Food and Drug 
Modernization Act of 1997, appears not 
to be comprehensive. One study found 
that, of 127 cancer protocols sponsored 
by pharmaceutical companies that met 
criteria for inclusion, only 48% were in 
fact submitted to the registry [5]. Thus, 
one can check a number of registries 
and still have little assurance that all 
the relevant trials of interest have been 
included.
Increasing the pressure on 
pharmaceutical companies to 
include more trials in registries, the 
International Committee of Medical 
Journal Editors has announced that, 
as a condition of considering a trial 
for publication, member journals will 
require its registration in a public 
trials registry [6]. Further, at the 
American Medical Association (AMA) 
Annual Meeting of the House 
of Delegates in June 2004, the 
AMA called on the Department 
of Health and Human Services 
to establish a comprehensive 
national registry. In September 
2004, an AMA trustee 
testiﬁ  ed in a United States 
Congressional hearing, 
outlining elements necessary 
to make such a registry 
effective [7]. Momentum 
for a comprehensive clinical 
trials registry is also building 
internationally [8]. 
In this essay, I argue that a 
highly valuable but underused 
registry and results database 
for US trials already exists 
within the Department of 
Health and Human Services, 
speciﬁ  cally within the Food and Drug 
Administration (FDA). 
New Drug Applications
Before a pharmaceutical company can 
conduct a US trial that it intends to use 
in support of a new drug application 
(NDA), it must ﬁ  rst register that trial 
with the FDA. Because the NDA forms 
the basis for marketing approval, it 
seems likely that the percentage of 
industry-sponsored trials that are 
registered with the FDA is very high. 
This registration takes the form of 
an investigational new drug (IND) 
application [9]. The IND contains a 
trial protocol; protocols for additional 
studies within the same clinical trials 
program are submitted as amendments 
to the IND. Later, when the sponsor 
has completed its clinical trials program 
and wishes to apply for marketing 
approval, it submits its NDA. 
The FDA then begins the NDA 
review process, during which a 
physician, a statistician, and a 
pharmacologist, among others, 
generate lengthy review documents 
[10]. These reviews not only 
address the sponsor’s analyses of the 
data on pivotal studies, but they often 
also include reanalyses by the reviewers 
using raw data obtained from the 
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sponsor. These analyses are conducted 
in adherence to the statistical methods 
set forth a priori in the original trial 
protocols. (By contrast, with most 
journal publications, it is usually 
not possible for the reader to verify 
whether what is presented as the main 
ﬁ  nding is consistent with the original 
hypothesis or whether it was a post hoc 
ﬁ  nding.) After the primary reviewers 
have written their reviews, shorter 
reviews are written by their superiors, 
with the process culminating in a 
decision about whether to approve the 
drug for the proposed indication. 
A Semi-Public Database
This process occurs entirely outside 
of the public domain. However, in 
the interest of making the FDA more 
“transparent,” and in accordance 
with the Electronic Freedom of 
Information Act [11], the FDA has, for 
the past several years, posted selected 
NDA reviews for approved drug–
indication combinations on the FDA 
Web site Drugs@FDA (http:⁄⁄www.
accessdata.fda.gov/scripts/cder/
drugsatfda/index.cfm). These NDA 
review documents are much more 
detailed than the resulting package 
insert and often more detailed than 
corresponding journal publications. 
For example, while the clinical 
trials section of the package insert is 
typically a few paragraphs long, the 
efﬁ  cacy portion of the clinical review 
usually runs tens of pages. Because 
the FDA is made aware of all studies 
that the sponsor plans to use in 
support of the NDA before they are 
conducted, and thus before there can 
be any selection based on outcome, 
these reviews cover not only studies 
that are positive (and more likely to 
be published in journals), but also 
studies whose outcome was negative 
or indeterminate. The sidebar gives 
an example of how NDA review 
documents at the FDA give valuable 
information about paroxetine for 
anxiety disorders.
FDA Reviews for All Approved 
Drugs Should Be Made Public
In the examples discussed in the 
sidebar, our having access to the 
FDA review documents allows us to 
become aware of, and see beyond, 
apparent publication bias. It is in the 
best interest of the public health for 
the FDA to make as many reviews 
available as possible. According to the 
FDA Web site, “As FDA continues to 
be one of the world’s leading agencies 
in its emphasis on openness and 
transparency, it is aware that making 
even more information available to 
the public will further the Agency’s 
mission to protect and promote public 
health and improve its credibility. 
For example, FDA has aggressively 
implemented the Electronic Freedom 
of Information Act…” [11]. 
Unfortunately, the availability of 
review documents on  Drugs@FDA is 
sporadic. To take additional examples 
from psychiatry, NDA reviews have 
been posted on Drugs@FDA for 
some approved drug–indication 
combinations, such as ﬂ  uoxetine for 
pediatric depression, and aripiprazole 
and quetiapine for schizophrenia. 
However, NDA reviews for many other 
drug–indication combinations have 
not been posted: the Prozac Weekly 
formulation of ﬂ  uoxetine, clozapine 
for suicidal behavior in patients with 
schizophrenia or schizoaffective 
disorder, and quetiapine for mania, 
among others. A review on paroxetine 
for pediatric depression, the subject 
of Elliot Spitzer’s suit against 
GlaxoSmithKline, is not posted. This is 
probably because this drug–indication 
combination was not approved; in fact, 
it is possible that GlaxoSmithKline 
did not ﬁ  le an NDA to be reviewed. 
However, I do not understand why, in 
cases where NDAs were both submitted 
and approved, such as the ones listed 
above, some reviews are posted while 
others are not. 
I therefore suggest that we increase 
access to the clinical trials registry 
and results database that already exist 
within the FDA. The agency could 
expand its implementation of the 
Electronic Freedom of Information 
Act and make all NDA reviews, at least 
for approved NDAs, available in the 
public domain. The act is written into 
the FDA portion of the Code of Federal 
Regulations as follows: “The Food and 
Drug Administration will make the 
fullest possible disclosure of records to 
the public, consistent with the rights 
of individuals to privacy, the property 
rights of persons in trade secrets and 
conﬁ  dential commercial or ﬁ  nancial 
information” [12].
Obstacles and Limitations
There would surely be obstacles. 
The pharmaceutical industry would 
vigorously invoke Exemption 4 of 
the Freedom of Information Act, 
the exemption for trade secrets and 
conﬁ  dential business information 
[13]. However, the FDA Freedom 
of Information Ofﬁ  ce already deals 
with conﬁ  dential and proprietary 
information by redacting or editing it 
out of the review documents before 
making them available. Within the 
FDA’s Freedom of Information Ofﬁ  ce, 
stafﬁ  ng would need to be greatly 
increased. Some oversight might be 
necessary to ensure that the taxpaying 
public has been granted the fullest 
possible access and that unwarranted 
redaction does not occur. Unless 
the Freedom of Information Act is 
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Paroxetine for Anxiety 
Disorders: Checking the 
Published Literature against 
the FDA Reviews
A Cochrane systematic review of 
antidepressants for generalized anxiety 
disorder [15] lists only one double-blind 
placebo-controlled study of paroxetine 
[16], a positive study. A PubMed search 
reveals no additional double-blind 
placebo-controlled studies. In accessing 
the review from Drugs@FDA (approval 
date April 2001), we learn that there 
were in fact three pivotal double-blind 
placebo-controlled studies. One of these 
studies corresponds to the published 
positive study noted above. Of the 
remaining two studies, both apparently 
unpublished, one was positive while the 
other was marginally positive. 
Turning to the controlled-release 
formulation of paroxetine (Paxil CR) for 
panic disorder, a review article states in 
its abstract that the drug “demonstrated 
efﬁ  cacy in three well designed studies 
in patients with panic disorder with or 
without agoraphobia” [17]. In reading 
the corresponding FDA statistical review, 
we verify that there were indeed three 
studies. However, the FDA statistical 
reviewer found that only one of these 
studies was strongly positive. A second 
study, judged “supportive” of efﬁ  cacy, had 
a marginally signiﬁ  cant (p = 0.039) result 
on a secondary observed-cases analysis, 
but a nonsigniﬁ  cant (p = 0.38) result on 
the primary efﬁ  cacy analysis deﬁ  ned 
a priori. The third study was clearly 
negative, with p-values of 0.33 and 0.57 
on the primary and secondary analyses, 
respectively.PLoS Medicine  |  www.plosmedicine.org 182
modiﬁ  ed, access would still likely be 
limited to approved NDAs. Data would 
remain unavailable for trials that did 
not lead to an approved NDA. 
It should be clariﬁ  ed that this 
resource does not compete with 
proposals by the AMA and other 
groups for clinical trial registries—
rather, it complements them. The AMA 
has proposed the creation of a registry 
that is comprehensive in scope. The 
FDA’s registry and results database 
are restricted to those trials aimed at 
supporting US marketing approval or 
a change in labeling in the US. While 
data from many studies conducted 
abroad are submitted to the FDA for 
this purpose, this is not the case for 
drugs for which the sponsor has elected 
not to seek approval for marketing 
in the US. Nor does the FDA review 
data from most trials funded by other 
US government agencies, such as the 
National Institutes of Health, or by 
foundations. And drug companies fund 
investigator-initiated trials that are 
often not registered with the FDA. 
To make the FDA review data 
more accessible and user-friendly, 
simple formatting changes would be 
needed. For those (few) reviews that 
are currently posted on Drugs@FDA, 
one can determine the indication 
being evaluated only after opening 
the document and paging through 
it. (Descriptive titles would be 
helpful, and these could be linked to 
ClinicalTrials.gov. Further, the trials 
reviewed could be identiﬁ  ed with 
a unique international identiﬁ  er, 
as promoted by the World Health 
Organization [14].) Despite the 
fact that the reviews are created in 
Microsoft Word and converted to PDF, 
the versions that appear on the Web 
site are no longer in a searchable text 
format. While the reviews tend to be 
well organized, the posted versions are 
difﬁ  cult to navigate because there is 
no hyperlinked table of contents. In 
addition to having these formatting 
issues addressed, clinicians and patients 
might beneﬁ  t from brief summaries, 
the writing of which might require the 
addition of new FDA staff.
Conclusion
Despite the limitations of the FDA’s 
database, making it public is a strategy 
that could be implemented both 
rapidly and easily by building upon 
existing infrastructure. While we await 
the creation of a clinical trials registry 
and results database that is truly 
comprehensive, we already have at our 
disposal one that could serve as a trove 
of in-depth and unbiased information 
on many, if not most, drugs currently 
marketed in the US.  
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